Press Releases

01/06/21

Strongbridge Biopharma plc Announces Preliminary Fourth Quarter and Full-Year 2020 Financial Results and Provides Corporate Update
11/24/20

Strongbridge Biopharma plc Announces Publication of Secondary Endpoints Data from Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome in the Journal, Pituitary
11/12/20

Strongbridge Biopharma plc Announces Participation in Two Upcoming Investor Conferences
10/29/20

Strongbridge Biopharma plc Reports Third Quarter 2020 Financial Results and Provides Corporate Update
10/22/20

Strongbridge Biopharma plc to Host Third Quarter 2020 Financial Results Conference Call on October 29, 2020
09/16/20

Strongbridge Biopharma plc Announces Pricing of Public Offering of Ordinary Shares
09/16/20

Strongbridge Biopharma plc Announces Proposed Public Offering of Ordinary Shares
09/08/20

Strongbridge Biopharma plc Provides Corporate Update
09/08/20

Strongbridge Biopharma plc Announces Positive and Statistically Significant Top-Line Results from the Pivotal Phase 3 LOGICS Study of RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome
08/04/20

Strongbridge Biopharma plc Reports Second Quarter 2020 Financial Results and Provides Corporate Update
07/28/20

Strongbridge Biopharma plc to Host Second Quarter 2020 Financial Results Conference Call on August 4, 2020
07/07/20

Strongbridge Biopharma plc Announces Appointment of John H. Johnson to Chief Executive Officer
07/01/20

Strongbridge Biopharma plc Announces Last Patient Completes Last Study Visit in the Randomized Withdrawal Phase of the LOGICS Trial Evaluating RECORLEV® (levoketoconazole) for Endogenous Cushing’s Syndrome
06/01/20

Strongbridge Biopharma plc to Present at the Jefferies Virtual Healthcare Conference
05/20/20

Strongbridge Biopharma plc Announces $30 Million Debt Facility with Avenue Venture Opportunities Fund, L.P.
05/18/20

Strongbridge Biopharma plc to Present at Upcoming 2020 Solebury Trout Virtual Global Healthcare Conference Series
05/11/20

Strongbridge Biopharma plc Announces Completion of Enrollment of Phase 3 LOGICS Study for RECORLEV® (levoketoconazole) for Endogenous Cushing’s Syndrome
05/06/20

Strongbridge Biopharma plc Reports First Quarter 2020 Financial Results and Provides Corporate Update
04/20/20

Strongbridge Biopharma plc to Host First Quarter 2020 Financial Results Conference Call on May 6, 2020
02/27/20

Strongbridge Biopharma plc to Present at the Cowen and Company 40th Annual Healthcare Conference
02/25/20

Strongbridge Biopharma plc Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Corporate Update
02/19/20

Strongbridge Biopharma plc to Host Fourth Quarter and Full-Year 2019 Financial Results Conference Call on February 25, 2020
01/30/20

Strongbridge Biopharma plc Announces New Employment Inducement Awards
01/09/20

Strongbridge Biopharma plc Announces Preliminary Fourth Quarter and Full-Year 2019 Financial Results and Provides Update on Corporate Priorities
11/18/19

Strongbridge Biopharma plc Announces Additional Steps to Improve Operational Efficiencies and Appoints New Lead Independent Director
11/12/19

Strongbridge Biopharma plc to Present at Two Upcoming Investor Conferences
11/07/19

Strongbridge Biopharma plc Reports Third Quarter 2019 Financial Results and Provides Corporate Update
11/05/19

Strongbridge Biopharma plc Announces CEO Transition Plan and Provides Preliminary Third Quarter 2019 Financial Results and Corporate Updates
10/29/19

Strongbridge Biopharma plc to Host Third Quarter 2019 Financial Results Conference Call on November 7, 2019
10/17/19

Strongbridge Biopharma plc Presents KEVEYIS® (dichlorphenamide) Primary Periodic Paralysis (PPP) Data at the 2019 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting
09/25/19

Strongbridge Biopharma plc to Present at the 2019 Cantor Global Healthcare Conference
09/19/19

Strongbridge Biopharma plc Announces RECORLEV™ (levoketoconazole) Phase 3 SONICS Data Published in The Lancet Diabetes & Endocrinology
09/03/19

Strongbridge Biopharma plc to Present at the H.C. Wainwright 21st Annual Global Investment Conference and the Janney Montgomery Scott Healthcare Conference 2019
08/13/19

Strongbridge Biopharma Announces Key Leadership Appointments to Support Next Stage of Growth
07/31/19

Strongbridge Biopharma plc Reports Second Quarter 2019 Financial Results and Provides Corporate Update
07/24/19

Strongbridge Biopharma plc to Host Second Quarter 2019 Financial Results Conference Call on July 31, 2019
07/19/19

Strongbridge Biopharma plc Announces New Employment Inducement Awards
07/01/19

Strongbridge Biopharma plc Added to the Russell 3000® and Microcap® Indexes
06/12/19

Strongbridge Biopharma plc to Present at the 2019 JMP Securities Life Sciences Conference
06/04/19

Strongbridge Biopharma plc Strengthens Senior Leadership Team with Key Promotion and Appointment
05/30/19

Strongbridge Biopharma plc to Present at the Jefferies 2019 Global Healthcare Conference
05/09/19

Strongbridge Biopharma plc Presents KEVEYIS® (dichlorphenamide) Primary Periodic Paralysis (PPP) Data at the 2019 American Academy of Neurology Annual Meeting
05/01/19

Strongbridge Biopharma plc Reports First Quarter 2019 Financial Results and Provides Corporate Update
04/25/19

Strongbridge Biopharma plc Announces Presentation of New Secondary Endpoint Data from Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome at the 2019 American Association of Clinical Endocrinologists Ann
04/24/19

Strongbridge Biopharma plc to Host First Quarter 2019 Financial Results Conference Call on May 1, 2019
04/15/19

Strongbridge Biopharma plc Announces Upcoming Presentation of New Data from Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome at the 2019 American Association of Clinical Endocrinologists (AACE) Annual
03/25/19

Strongbridge Biopharma plc Announces Presentation of New Data Analyses from Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Potential Treatment of Endogenous Cushing’s Syndrome
03/11/19

Strongbridge Biopharma plc Announces Top-Line Results from Extended Evaluation Phase of the Pivotal Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Potential Treatment of Endogenous Cushing’s Syndrome
03/08/19

Strongbridge Biopharma plc Announces New Employment Inducement Awards
03/04/19

Strongbridge Biopharma plc Announces Upcoming Presentation of New Data from Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome at the 2019 Annual Meeting of the Endocrine Society (ENDO)
02/27/19

Strongbridge Biopharma plc to Present at the Cowen and Company 39th Annual Healthcare Conference and the Oppenheimer 29th Annual Healthcare Conference
02/26/19

Strongbridge Biopharma plc Reports Fourth Quarter and Full-Year 2018 Financial Results
02/22/19

Strongbridge Biopharma plc Announces Annual General Meeting of Shareholders
02/19/19

Strongbridge Biopharma plc to Host Fourth Quarter and Year-End 2018 Financial Results Conference Call on February 26, 2019
12/19/18

Strongbridge Biopharma plc Announces Closing of Transaction with Novo Nordisk to Transfer the Rights to MACRILEN™ (macimorelin) in the United States and Canada
11/20/18

Strongbridge Biopharma plc Announces Presentation of New Data Comparing the In Vitro Effects of Levoketoconazole, the Active Ingredient in RECORLEV™, and Ketoconazole on Human Cortisol Production
11/05/18

Strongbridge Biopharma plc to Present at the Stifel 2018 Healthcare Conference
10/31/18

Strongbridge Biopharma plc Reports Third Quarter 2018 Financial Results and Provides Corporate Update
10/31/18

Strongbridge Biopharma plc Enters into Agreement for Novo Nordisk to Acquire the U.S. and Canadian Rights to MACRILEN™ (macimorelin)
10/22/18

Strongbridge Biopharma plc Presents Detailed Initial Results from Pivotal Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome at the 18th Annual Congress of the European NeuroEndocrine Association
09/18/18

Strongbridge Biopharma plc to Participate in Two Upcoming Healthcare Investor Conferences
08/28/18

Strongbridge Biopharma plc Announces Presentations at Two Upcoming Investor Conferences
08/28/18

Strongbridge Biopharma plc Announces New Employment Inducement Awards
08/15/18

Strongbridge Biopharma plc Announces Termination of Public Offering of Ordinary Shares
08/14/18

Strongbridge Biopharma plc Announces Proposed Public Offering of Ordinary Shares
08/08/18

Strongbridge Biopharma plc Reports Second Quarter 2018 Financial Results and Provides Corporate Update
08/08/18

Strongbridge Biopharma plc Announces Positive Top-Line Results from the Pivotal Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome
06/06/18

Strongbridge Biopharma plc to Present at the JMP Securities Life Sciences Conference
05/31/18

Strongbridge Biopharma plc to Present at the Jefferies 2018 Global Healthcare Conference
05/10/18

Strongbridge Biopharma plc Reports First Quarter 2018 Financial Results and Provides Corporate Update
05/03/18

Strongbridge Biopharma plc Announces New Employment Inducement Awards
04/26/18

Strongbridge Biopharma plc to Host First Quarter 2018 Financial Results Conference Call on May 10, 2018
04/02/18

Strongbridge Biopharma plc Announces Dosing of First Four Patients in LOGICS, a Second Global Phase 3 Study of RECORLEV™ (levoketoconazole) in Endogenous Cushing’s Syndrome
03/26/18

Strongbridge Biopharma plc to Host Investor and Analyst Day on April 5, 2018
03/20/18

Strongbridge Biopharma Announces Issuance of Patent for RECORLEV™ (levoketoconazole) for the Treatment of Cushing’s Syndrome
03/18/18

Strongbridge Biopharma plc Announces Presentation of New Data Demonstrating That Levoketoconazole is a Potent Inhibitor of Human Enzymes Controlling Cortisol Synthesis
03/12/18

Strongbridge Biopharma plc Reports Full-Year 2017 Financial Results
03/06/18

Strongbridge Biopharma plc to Present at the Cowen and Company 38th Annual Healthcare Conference and the Oppenheimer 28th Annual Healthcare Conference
03/05/18

Strongbridge Biopharma plc to Present KEVEYIS® (dichlorphenamide) Primary Periodic Paralysis Data at the 2018 American Academy of Neurology Annual Meeting
02/28/18

Strongbridge Biopharma plc to Host Conference Call on March 12, 2018 to Announce Fourth Quarter and Year-End 2017 Financial Results and Provide Corporate Update
02/26/18

Strongbridge Biopharma plc Announces Underwriters’ Partial Exercise of Option to Purchase Additional Shares
02/23/18

Strongbridge Biopharma plc Announces Annual General Meeting of Shareholders
01/25/18

Strongbridge Biopharma plc Announces Pricing of Public Offering of Ordinary Shares
01/23/18

Strongbridge Biopharma plc Announces Proposed Public Offering of 5 Million Ordinary Shares
01/18/18

Strongbridge Biopharma Receives Notice of Allowance from U.S. Patent and Trademark Office for New Patent Covering RECORLEV™ (levoketoconazole) for the Treatment of Cushing’s Syndrome
01/17/18

Strongbridge Biopharma plc Announces Acquisition of the U.S. and Canadian Rights to MACRILEN™ (macimorelin) from Aeterna Zentaris
12/14/17

Strongbridge Biopharma plc Announces New Employment Inducement Awards
12/13/17

Strongbridge Biopharma plc Added to the NASDAQ Biotech Index
11/14/17

Strongbridge Biopharma plc Provides Corporate Update and Reports Third Quarter 2017 Financial Results
11/07/17

Strongbridge Biopharma plc to Present at the Stifel 2017 Healthcare Conference
11/06/17

Strongbridge Biopharma plc to Host Third Quarter 2017 Financial Results Conference Call on November 14, 2017
10/06/17

Strongbridge Biopharma plc Announces Closing of Public Offering of Ordinary Shares
10/04/17

Strongbridge Biopharma plc Announces Pricing of Public Offering of Ordinary Shares
10/03/17

Strongbridge Biopharma plc Announces Proposed Public Offering of Ordinary Shares
09/25/17

Strongbridge Biopharma plc Launches the Uncovering Periodic Paralysis Genetic Testing Program
09/18/17

Strongbridge Biopharma plc to Present at the Cantor Fitzgerald Global Healthcare Conference
09/05/17

Strongbridge Biopharma plc to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
08/10/17

Strongbridge Biopharma plc to Present at the Canaccord Genuity 37th Annual Growth Conference
08/07/17

Strongbridge Biopharma plc Provides Updates on KEVEYIS® Launch and Recent Business Highlights, and Reports Second Quarter 2017 Financial Results
07/31/17

Strongbridge Biopharma plc to Host Conference Call on August 7, 2017 to Provide KEVEYIS® Launch Update and Report Second Quarter 2017 Financial Results
07/17/17

Strongbridge Biopharma plc Secures $53 Million Financing From CRG
06/27/17

Strongbridge Biopharma plc Completes Target Enrollment of 90 Patients in the Phase 3 SONICS Study Evaluating RECORLEV™ (levoketoconazole) in Endogenous Cushing’s Syndrome
06/26/17

Strongbridge Biopharma plc Added to the Russell 3000® Index
06/23/17

Strongbridge Biopharma plc Announces New Employment Inducement Awards
06/13/17

Strongbridge Biopharma plc to Participate in the JMP Securities Life Science Conference
05/25/17

Strongbridge Biopharma plc to Present at the Jefferies 2017 Global Healthcare Conference
05/16/17

Strongbridge Biopharma plc Provides Corporate Update and Reports First Quarter 2017 Financial Results
05/03/17

Strongbridge Biopharma plc Announces New Employment Inducement Awards
03/27/17

Strongbridge Biopharma plc Provides Corporate Update and Reports Full-Year 2016 Financial Results
03/17/17

Strongbridge Biopharma plc Announces New Employment Inducement Awards

Releaseb2d1b514-b887-4235-854f-959a299c821b_2254733.pdf 22.9 KB
03/14/17

Strongbridge Biopharma plc to Present at the 27th Annual Oppenheimer Healthcare Conference and the 16th Annual Needham Healthcare Conference

Release9bc6bd9f-8858-46a5-a48d-206af834da5a_2253691.pdf 21.2 KB
02/27/17

Strongbridge Biopharma plc to Present at the 37th Annual Cowen and Company Healthcare Conference and the 29th Annual ROTH Conference

Release27a45c88-a905-4986-8a3b-35004040da4e_2249604.pdf 21 KB
02/24/17

Strongbridge Biopharma plc Announces Annual General Meeting of Shareholders

Release01def22f-c75c-410b-b0a1-b74b77ac2cb0_2249190.pdf 19.1 KB
02/02/17

Strongbridge Biopharma plc to Participate in the Canaccord Genuity Rare Disease and BioPharma One-on-One Day

Release26fd8f84-07c8-4332-97bd-285c93ad9292_2241862.pdf 20 KB
01/09/17

Strongbridge Biopharma plc Expands Commercial Capabilities with Two Rare Disease Executive Hires

Release2bbf207d-9c89-4d96-95b3-28931a1b1c3d_2234928.pdf 30.2 KB
01/04/17

Strongbridge Biopharma plc to Present at Biotech Showcase 2017

Released5330215-98cc-4639-ac6c-c93a6028c3b6_2233777.pdf 21 KB
12/29/16

Strongbridge Biopharma plc Announces Closing of $35 Million Equity Financing and $40 Million Credit Facility

Release083fd7be-4e10-4d8d-bf88-08f096d9931e_2233075.pdf 27.3 KB
12/23/16

Strongbridge Biopharma plc Provides Corporate and Financial Update

Releasefdce20d7-28a6-49f8-80a3-77cdf333b38e_2231584.pdf 435.3 KB
12/23/16

Strongbridge Biopharma plc Announces Acquisition of U.S. Rights to KEVEYIS® From Taro

Releasee3a876a9-7042-4222-ac03-06c5e33019b2_2231581.pdf 30.2 KB
12/23/16

Strongbridge Biopharma plc Announces $35 Million Equity Financing

Release0f2d2b06-aa18-4301-a3e7-a1292f26d5c6_2231578.pdf 24.7 KB
11/29/16

Strongbridge Biopharma plc Announces Promotion of Fredric Cohen, M.D., to Chief Medical Officer

Release0ab40f46-c938-470b-86f0-e37c7f9eb88f_2226106.pdf 23.5 KB
10/03/16

Strongbridge Biopharma plc Announces Appointment of Jeffrey W. Sherman, M.D., FACP, to Board of Directors

Release7a90a801-2cdb-4ebe-ad21-88dfaace3b4a_2208393.pdf 26.1 KB
07/06/16

Strongbridge Biopharma plc Announces Presentation at Cantor Fitzgerald’s 2nd Annual Healthcare Conference

Release8375dfe0-47ca-4f02-8981-52f3b123d046_2182218.pdf 19.5 KB
06/14/16

Strongbridge Biopharma plc to Participate in the JMP Securities Life Sciences Conference and 3rd Annual ROTH Healthcare Day in London

Release1d523443-5578-4cd7-951b-ac548c43a31a_2177351.pdf 20.3 KB
06/09/16

Strongbridge Biopharma plc Announces Executive Promotion and Leadership Transition

Release2e33e66e-4f36-4167-a5e2-9facbd4e1a2b_2176689.pdf 24.9 KB
06/02/16

Strongbridge Biopharma plc Announces Presentation at Jefferies 2016 Healthcare Conference

Releasef7651646-4023-41d8-be9b-be74753acf29_2174723.pdf 19.4 KB
06/02/16

EY Announces Strongbridge Biopharma's President and CEO Matthew Pauls is Named an EY Entrepreneur Of The Year® 2016 Finalist in Greater Philadelphia

Release5c777f7c-6b48-407e-b9c0-5ed84781d256_2174476.pdf 14.7 KB
05/31/16

Strongbridge Biopharma plc Announces Presentation of COR-003 and COR-005 Data at the European Congress of Endocrinology

Release2951758d-ee32-4d74-b790-2c65c097641a_2173388.pdf 25.8 KB
05/17/16

Strongbridge Biopharma plc Reports First Quarter 2016 Financial Results

Release76ca7abe-ee10-481d-8b6a-7b61d4b2a224_2168926.pdf 409.1 KB
05/05/16

Strongbridge Biopharma plc Announces Presentation at Bio€quity Europe 2016

Release8dfc5130-682d-411e-a30c-e139ffd33ba9_2165537.pdf 19 KB
04/06/16

Strongbridge Biopharma plc Announces Presentation at 15th Annual Needham Healthcare Conference

Release37228c6a-bd1b-49d0-8923-551bc257a18c_2154542.pdf 19 KB
04/04/16

Strongbridge Biopharma plc Announces Presentation of COR-003 Data at the Endocrine Society’s 2016 Annual Conference

Release20c4098f-4b8b-4f18-8fdd-9397066fd386_2153702.pdf 23.5 KB
03/24/16

Strongbridge Biopharma plc Reports Full-Year 2015 Financial Results

Releasec91e0f2e-81b1-4f8a-8672-e205b96f548a_2150693.pdf 409.2 KB
03/07/16

Strongbridge Biopharma plc Provides Update on Corporate Progress

Releasecaf946ce-99bd-47e4-888c-3b08fdb6735c_2146280.pdf 28.1 KB
02/25/16

Strongbridge Biopharma plc Announces Presentations at Two Upcoming Investor Conferences

Release7597bc38-f4b7-4442-ae41-a0bc26ba0ac5_2143205.pdf 21 KB
02/18/16

Strongbridge Biopharma Announces Annual General Meeting of Shareholders

Released63a40b3-18fa-46b0-ac3d-789f89fc59b0_2140723.pdf 22 KB
02/18/16

Strongbridge Biopharma plc Announces Participation at SunTrust Robinson Humphrey’s 2016 Orphan Drug Day

Release0a2fd81c-ae36-45de-92fc-9807cb91d701_2140432.pdf 18.9 KB
12/16/15

Strongbridge Biopharma plc Announces Presentation at Biotech Showcase 2016
12/07/15

Strongbridge Biopharma Announces Issuance of U.S. Patent for Investigational COR-003 (levoketoconazole) in Treatment of Endogenous Cushing's Syndrome
12/01/15

Strongbridge Biopharma plc Announces Presentation at the 26th Annual Oppenheimer Healthcare Conference
11/23/15

Strongbridge Biopharma plc Announces Presentation at Arctic Biotech Seminar
11/18/15

Strongbridge Biopharma plc Provides Update on Corporate Progress
11/04/15

Strongbridge Biopharma plc Announces Presentation at the Stifel 2015 Healthcare Conference
11/03/15

Strongbridge Biopharma plc Announces Data Presentation at the Society for Endocrinology BES 2015 Conference
10/21/15

Strongbridge Biopharma plc Announces Closing of Initial U.S. Public Offering
10/16/15

Strongbridge Biopharma plc Announces Pricing of Its Initial U.S. Public Offering
09/21/15

Strongbridge Biopharma Plc Announces Launch of Its Proposed Initial U.S. Public Offering

Release1bb7ce3e-ecc9-4a6b-b54b-81e5b83bcf62_2090287.pdf 15.1 KB
09/15/15

Strongbridge Biopharma plc Announces Appointment of Garheng Kong, M.D., Ph.D., MBA, to its Board of Directors

Release7776c398-bb50-4061-afd2-8f8354aaf5ac_2090284.pdf 16 KB
09/04/15

Strongbridge Biopharma plc Announces Appointment of Matthew Pauls to its Board of Directors

Releasef228737d-35de-4a18-bb9c-dba2620d28c3_2090277.pdf 16.3 KB
09/04/15

Cortendo plc Changes Name to Strongbridge Biopharma plc

Released1e3b2d4-f5dc-4694-afa7-8a55201357a2_2090265.pdf 10.6 KB
09/04/15

Cortendo plc Announces Reverse Share Split

Releasec8a80494-94b1-4262-9f78-eafc6dd0ed44_2090264.pdf 11.7 KB
08/31/15

Cortendo Announces Filing of Registration Statement for Proposed Initial Public Offering

Releaseedab3568-5fd9-42cf-80b7-bc2b3f78fb38_2090248.pdf 8.7 KB
08/28/15

Interim Financial Results For The Six Months Ended June 30, 2015
08/04/15

Notification of trade

Release8719202f-6aa4-49fb-8412-01a70496ca7d_2075690.pdf 5.6 KB
08/03/15

Cortendo Announces Plans to Redomicile the Cortendo Group’s Parent Company from Sweden to Ireland By Means of an Exchange Offer

Release35e455d7-6eb6-40ee-affb-88572a38c2b7_2074932.pdf 19.3 KB
07/20/15

Cortendo Announces Plans to Conduct Registered Initial Public Offering of Its Common Shares

Release48671ffa-b90b-4205-bb93-8e5239224a73_2074944.pdf 6.3 KB
07/02/15

Cortendo Provides 2015 Half-Year Update on Corporate Progress

Release31ca2a37-e95a-41e0-87a5-e51cfe12f4f8_2074946.pdf 28 KB
06/25/15

Resolutions by the Annual General Meeting in Cortendo AB (publ)

Release2a0dc830-3d1f-4984-9906-8f8e56db9127_2074948.pdf 18.1 KB
05/22/15

Cortendo Announces Notice of Annual General Meeting

Releaseb98014a9-a03c-48d0-a7db-9a3c2d151143_2074952.pdf 12.2 KB
05/22/15

Cortendo offentliggör kallelse till årsstämma

Release91359b5e-506a-4417-a877-14b9cc30d7d6_2074951.pdf 13 KB
05/19/15

Notification of Trade

Release2ec563bb-6968-4a1f-bc95-497cc8d45aa5_2074956.pdf 12.6 KB
05/15/15

Cortendo Adds Two Late-Stage Assets to Its Rare Endocrine Disease Franchise and Announces Related $33.2 Million Financing

Release707aa6d3-2671-4f92-af80-55404501f720_2074969.pdf 22 KB
05/14/15

Cortendo and Antisense Therapeutics Announce Licensing Agreement for ATL1103 for Acromegaly

Release2d84a083-347d-4028-8838-4555f257460f_2074972.pdf 29.1 KB
04/08/15

Cortendo AB Joins National Organization for Rare Disorders (NORD)® Corporate Council

Releasecbfc00e4-8419-460f-bb8a-e45f2f08e1ad_2074975.pdf 18.8 KB
03/23/15

Cortendo AB Announces Appointments of A. Brian Davis as Chief Financial Officer and Stephen Long as Chief Legal Officer

Release76ee7b92-8822-46bd-b2c4-5f8dbc652c77_2074977.pdf 19.2 KB
03/18/15

Cortendo AB Names John H. Johnson as Chairman and Appoints Richard Kollender as Director

Release6962fe1b-007f-4d02-9a1f-eee278aa23e3_2074979.pdf 18.6 KB
03/17/15

Election of new board members by Extraordinary General Meeting of Cortendo AB

Release038839f4-9844-40b7-a009-908d62a49227_2074981.pdf 14.2 KB
03/11/15

Interim report for the fourth quarter and full year 2014

Release96375072-7ef3-4cb3-b816-273dbe857316_2074982.pdf 7.7 KB
02/27/15

Cortendo utfärdar kallelse till extra bolagsstämma

Released77c1a3e-7db5-4144-a387-39e02ed51d7b_2074986.pdf 18.7 KB
02/27/15

Cortendo Announces Notice of Extraordinary General Meeting

Releasec240d886-2321-4787-8184-5499ab759c4e_2074985.pdf 27.1 KB
02/27/15

Cortendo Announces Proposed Changes to Board of Directors

Release41e44fc3-5aa6-49bc-b7a4-b307384deb00_2074984.pdf 19.8 KB
02/26/15

Cortendo to Present at Upcoming Investor Conferences

Release99261b96-87b2-4eb6-b97b-b2c6425b9995_2074987.pdf 14.5 KB
02/23/15

Cortendo to Join Patients, Families and Pennsylvania Legislators to Raise Awareness for Rare Diseases

Releasef6568e38-15fe-4772-a931-56a6c6cca991_2074988.pdf 20 KB
02/11/15

Cortendo Completes $26.4M in Private Placement from Leading U.S. and EU Investors

Releaseac25ffdb-0507-46fc-9ed8-9c9f73b9ffca_2074991.pdf 15.9 KB
02/03/15

Resolutions on new share issues by Extraordinary General Meeting and Board of Directors of Cortendo AB

Releasefff0847d-1aa0-4af2-b41b-08937b899b80_2075021.pdf 17.1 KB
02/02/15

Cortendo to Present at the 17th Annual BIO CEO & Investor Conference

Release858701d5-58e2-4ba3-a376-676d75cac47a_2075023.pdf 15.1 KB
01/29/15

COR-003 Phase 3 Study Protocol to be Presented at ENDO 2015: The Endocrine Society’s 97th Annual Meeting & Expo

Release68bb467f-192d-40de-b149-70645f9c86ca_2075025.pdf 10.4 KB
01/28/15

The Journal Diabetes Publishes Pre-clinical Data on Cortendo’s Novel Diabetes Treatment, BP-2001

Release48531f90-a5fd-4c64-a672-3b7b3b65b467_2075027.pdf 19.5 KB
01/27/15

Notification of Trade

Released83ddfd1-2479-4b66-b89b-cec33aad55aa_2075031.pdf 13.2 KB
01/15/15

Cortendo Announces Notice of Extraordinary General Meeting

Release2ba4cb75-88b7-4555-991d-9fa0cd4154d9_2075035.pdf 26.4 KB
01/15/15

Kallelse till extra bolagsstämma i Cortendo AB (publ)

Release5714f7c2-8817-40f6-b8c9-e9575ec4dfb5_2075033.pdf 15.3 KB
01/13/15

Cortendo AB Raises up to $27.5M in Additional Private Placement with Leading U.S. and EU Healthcare Investors

Release7cc80a12-e529-4efd-bdf7-be16d94f7714_2075038.pdf 17.1 KB
01/08/15

- CORRECTED – Cortendo to Present at the 7th Annual Biotech Showcase Conference in San Francisco on Jan. 14

Release29e1d59b-b6dc-4298-9eb0-3e4aeb0ccdc5_2075040.pdf 14.2 KB
01/08/15

Cortendo to Present at the 7th Annual Biotech Showcase Conference in San Francisco on Jan. 14

Release8319d0c1-29ae-45f8-81e1-241259b5b8e6_2075042.pdf 13.9 KB
12/05/14

Cortendo AB formally informs Oslo Børs that it will not pursue Oslo Axess listing

Releasefdbcd3df-7928-4312-8db1-9ddbfce214ab_2075121.pdf 15.9 KB
12/01/14

Extraordinary General Meeting in Cortendo AB

Releaseaf829dc4-ef78-4e46-8fa6-cdb5907e60b1_2075134.pdf 18.5 KB
11/19/14

Cortendo Appoints Ruth Thieroff-Ekerdt as Chief Medical Officer

Releasee0825d42-c3ee-4386-9842-1b9951ccd159_2075140.pdf 18.3 KB
11/18/14

Interim Report, Q3 2014

Releasef8ac81ea-8a34-4156-8914-fe94dedb5e89_2075142.pdf 8.6 KB
10/30/14

Cortendo Announces Notice of Extraordinary General Meeting

Release0716b5a5-59cb-405c-9717-03710ad4fd72_2075156.pdf 4.8 KB
10/30/14

Cortendo Announces HealthCap Leads $11M (NOK 73.4M) Private Placement

Releasebec8e450-4460-4459-bfd9-2374b4658139_2075158.pdf 27.3 KB
10/30/14

Kallelse till extra bolagsstämma i Cortendo AB (publ)

Release28da61c5-3af7-4623-b33a-14718de153a3_2075152.pdf 7.8 KB
10/09/14

Cortendo Appoints Robert Lutz as Chief Business Officer

Releasebe1566bd-b2d8-4866-8e1b-1de2e7ee4744_2075159.pdf 18 KB
10/03/14

Cortendo AB to Present at the 13th Annual BIO Investor Forum in San Francisco October 7, 2014

Release0a985d34-ff91-430f-82de-408706c1d0f8_2075465.pdf 14.2 KB
09/30/14

Cortendo AB to Present at the Epic Biotech Conference in London on October 2, 2014

Releaseb269c9c3-243b-4c1d-9ce7-fabe699a17bf_2075489.pdf 15.9 KB
09/29/14

Cortendo AB to Present at the 14th Annual BIOTECH in Europe Forum in Basel September 30, 2014

Released190582c-20ef-4af7-a5ca-9459679fb982_2075496.pdf 14.3 KB
08/26/14

Interim Report, Q2 and H1 2014

Release0c0aba5f-3ad7-4007-bfe5-0b81713ed490_2075504.pdf 6.4 KB
08/12/14

First Patient Enrolled into NormoCort Phase 3 SONICS Trial Following a Successful EU Investigator Meeting

Releaseba0dec0d-23ee-4431-a4b1-e070f4108296_2075510.pdf 15.3 KB
08/07/14

CORTENDO Appoints Matthew Pauls As Chief Executive Officer

Release6e2db373-fb2b-4103-93e4-722111166404_2075524.pdf 17.6 KB
07/09/14

CORTENDO Reports Continued Progress On Phase 3 SONICS Trial

Release79bf6a15-173a-4c78-a0bd-619fd1a45004_2075529.pdf 14.7 KB
06/02/14

Interim Report, First Quarter 2014

Releasee2cdcd44-90f2-4836-bac5-543a3aa67546_2075530.pdf 30.5 KB
05/19/14

CORTENDO Business Strategy and Organizational Update

Release3eff8720-bed8-47fd-82b6-53e70ba57a79_2075531.pdf 15.6 KB
05/15/14

Notice of Annual General Meeting

Releasea84e60cc-5dac-4a72-9480-35255eae0a22_2075546.pdf 18.3 KB
05/15/14

Call for Annual General Meeting (Swedish)

Release92394f9f-c9f8-4a0d-96ad-40550a38a1b7_2075550.pdf 4.1 KB
03/18/14

BioPancreate Receives First US Patent Notice of Allowance on Novel Diabetes Technology

Releasee8bbf541-07f4-4435-8343-5d5ee65620fb_2075553.pdf 16.8 KB
03/03/14

Interim report for the fourth quarter and full year 2013

Releasea22ce9fd-d528-47ad-b7df-834b74800789_2075554.pdf 6.1 KB
01/20/14

CORTENDO AB shareholders unanimously support all proposals at Extraordinary Shareholder’s Meeting

Release526f906c-f497-493d-aacf-590f04898d2e_2075561.pdf 11.7 KB
01/16/14

Dr. John Amatruda Joins Cortendo As Acting Chief Medical Officer

Releasede117c1b-e104-4b00-9a26-b99040459da7_2075565.pdf 14.6 KB

Investors

Press Releases

Keyword Search